Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889298 | 0.83 | HPGD (0.39) | CYP3A4MEN1NPC1USP2EGFR | |
| SCHEMBL18112469 | 0.77 | CYP3A4 (0.50) | CYP3A4MEN1NPC1USP2EGFR | |
| SCHEMBL4892232 | 0.74 | GRIN2D (0.34) | — | |
| SCHEMBL4885560 | 0.71 | CYP3A4 (0.56) | CYP3A4MEN1NPC1USP2EGFR | |
| SCHEMBL14143885 | 0.71 | HPGD (0.48) | CYP3A4MEN1NPC1USP2EGFR | |
| SCHEMBL4886977 | 0.70 | CYP3A4 (0.35) | CYP3A4HPGDTSHRHSD17B10 | |
| SCHEMBL4891636 | 0.70 | — | — | |
| SCHEMBL4889535 | 0.69 | HTT (0.39) | CYP3A4MEN1NPC1LMNACYP1A2 | |
| SCHEMBL4889462 | 0.69 | — | — | |
| SCHEMBL12658942 | 0.68 | GRIN2D (0.36) | ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817318-B1 | STABILIZING METHOD AND STABILIZED COMPOSITION FOR ARYL BORON COMPOUNDS | NIPPON CATALYTIC CHEM IND (JP) | 2013-08-28 | — | — | EP | disclosed |
| US-20080154065-A1 | Stabilizing Method and Stabilized Composition for Aryl Boron Compounds | NIPPON SHOKUBAI CO., LTD. (JP) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080154065-A1 | Stabilizing Method and Stabilized Composition for Aryl Boron Compounds | AR, AHR, BCL6 | CYP3A4 2401/4885MEN1 1014/4885NPC1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.